PT  - JOURNAL ARTICLE
AU  - Spevak, Aimee
ED  - Sabatine, Marc S.
TI  - Evolocumab Effectively Lowers LDL-C, Decreases Cardiovascular Outcomes in OSLER
DP  - 2015 May 24
TA  - MD Conference Express
PG  - 10--11
VI  - 15
IP  - 5
4099  - http://mdc.sagepub.com/content/15/5/10.short
4100  - http://mdc.sagepub.com/content/15/5/10.full
AB  - The OSLER extension studies randomized patients to receive standard of care or standard of care plus evolocumab. At 1 year, evolocumab lowered low-density lipoprotein cholesterol by 61% and demonstrated preliminary evidence that this may reduce the risk of cardiovascular events. Evolocumab was well tolerated across all gradients of achieved low-density lipoprotein cholesterol levels.